SCHEMBL353266

SCHEMBL353266

O=C1C=CC2=C(C[CH]S2)C1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL908444 0.64
SCHEMBL277815 0.63
SCHEMBL10790767 0.59 GSK3A (0.46) GSK3AGSK3B
SCHEMBL366153 0.58 GSK3A (0.71) GSK3AGSK3B
SCHEMBL7061280 0.55 GSK3A (0.40) GSK3AGSK3B
SCHEMBL5468608 0.55 GSK3A (0.40) GSK3AGSK3B
SCHEMBL943110 0.55 GSK3A (0.46) GSK3AGSK3B
SCHEMBL30866089 0.55
SCHEMBL30379276 0.55 GSK3A (0.46) GSK3AGSK3B
SCHEMBL9527717 0.55 GSK3A (0.46) GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199940-B2 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor ARENA PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-9102627-B2 Processes for preparing 3-benzazepines ARENA PHARMACEUTICALS, INC. 2015-08-11 US disclosed
US-20130296321-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. 2013-11-07 US disclosed
US-8481535-B2 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor ARENA PHARMACEUTICALS, INC. (US) 2013-07-09 US disclosed
US-20130165648-A1 PROCESSES FOR PREPARING 3-BENZAZEPINES ARENA PHARMACEUTICALS, INC. 2013-06-27 US disclosed
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 US disclosed
US-8343999-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-01 US disclosed
US-8293919-B2 Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-10-23 US disclosed
US-8273772-B2 Heteroaryl compounds as P2Y1 receptor inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-09-25 US disclosed
US-8268826-B2 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV INCYTE CORPORATION (US) 2012-09-18 US disclosed
US-20080207898-A1 PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS WYETH (US) 2008-08-28 US disclosed
US-20080194836-A1 Process for Preparing Substituted Phenylpyrazole Ureas ARENA PHARMACEUTICALS, INC. 2008-08-14 US disclosed
US-7388021-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL MYERS SQUIBB COMPANY (US) 2008-06-17 US disclosed
US-20080108586-A1 COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION INCYTE CORPORATION (US) 2008-05-08 US disclosed
US-20080004263-A1 Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof ARENA PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 US disclosed
US-20060211720-A1 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 US disclosed
US-20060166997-A1 Phenylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 US disclosed
US-20050267119-A1 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US disclosed
US-20050261310-A1 Piperazinylpiperidine derivatives as chemokine receptor antagonists INCYTE CORPORATION 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296321-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR2A, HTR5A, HTR2C GSK3A 1936/4885GSK3B 1752/4885
US-20080194836-A1 Process for Preparing Substituted Phenylpyrazole Ureas HTR5A, HTR2A, HTR2C GSK3A 3693/4885GSK3B 3481/4885
US-20130165648-A1 PROCESSES FOR PREPARING 3-BENZAZEPINES HTR3C, HTR3B, HTR3A GSK3A 631/4885GSK3B 509/4885
US-20080207898-A1 PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS ADH1A, ADH1C, ADH5 GSK3A 4109/4885GSK3B 3532/4885
US-20050261310-A1 Piperazinylpiperidine derivatives as chemokine receptor antagonists CCR5, CCR2, CXCR5 GSK3A 3035/4885GSK3B 2698/4885
US-20050267119-A1 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions P2RY1, P2RY11, P2RY2 GSK3A 4462/4885GSK3B 4535/4885
US-20060166997-A1 Phenylglycinamide derivatives useful as anticoagulants TFPI, SERPINC1, SERPINE1 GSK3A 575/4885GSK3B 921/4885
US-20060211720-A1 Heterocyclic compounds as inhibitors of factor VIIa TFPI, F7, HABP2 GSK3A 479/4885GSK3B 695/4885
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F12, F7, F2 GSK3A 923/4885GSK3B 1021/4885
US-20080108586-A1 COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION CCR5, HAVCR2, CXCR3 GSK3A 1342/4885GSK3B 1329/4885
US-20080004263-A1 Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof FSHR, GNRHR, LHCGR GSK3A 4660/4885GSK3B 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.